Scenario 2 - Neprilysin inhibitors in heart failure: safety and adverse events

26 August 2018 (11:30 - 11:55)

Organised by:

Slides

Sign in for access options

About the speaker

Assistant Professor Marta Izabela Kaluzna-Oleksy

Poznan University of Medical Sciences, Poznan (Poland)

5 More presentations in this session

Presentation thumbnail

Safety first: avoiding adverse events with new cardiovascular drugs - Panel

Presentation thumbnail

Introduction - Safety first: avoiding adverse events with new cardiovascular drugs

Doctor M. Alonso Garcia (London, GB)

Presentation thumbnail

Scenario 1 - Adverse events of new lipid lowering drugs.

Doctor T. Hall (Oslo, NO)

Presentation thumbnail

Scenario 3 - Long-term safety of new anti-diabetic drugs.

Professor A. Niessner (Vienna, AT)

Presentation thumbnail

Safety first: avoiding adverse events with new cardiovascular drugs - Take Home Message.

Professor J. Tamargo (Madrid, ES)

Access the full session

Session thumbnail

Meet the Experts - Safety first: avoiding adverse events with new cardiovascular drugs

The Event

ESC Congress 2018

26 August 2018 11:30 CET

You may be interested in

Congress Presentation

Angiotensin receptor-neprilysin inhibition in patients with de novo acute decompensated heart failure: a prespecified subgroup analysis of the PIONEER-HF trial

1 September 2019

Congress Session

Evolving treatment paradigms in heart failure: from SGLT2 inhibition to transthyretin stabilisation and beyond

20 May 2025

Congress Presentation

Safe electrophysiologic profile of the neprilysin-inhibitor sacubitril in combination with different antiarrhythmic drugs

29 August 2022

Congress Presentation

Discussant review - PERSPECTIVE.

26 August 2022

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources